Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
Status:
RECRUITING
Trial end date:
2029-03-31
Target enrollment:
Participant gender:
Summary
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non-HDL-C) among at-risk Emergency Department (ED) patients who are not already receiving guideline-directed outpatient preventive care and (2) inform our understanding of patient adherence and determinants of implementation for ED-based cardiovascular disease prevention strategies.
Phase:
PHASE2
Details
Lead Sponsor:
Wake Forest University Health Sciences
Collaborators:
National Heart, Lung, and Blood Institute (NHLBI) National Institutes of Health (NIH)